Nephros Provides Corporate Update( NEW YORK Nov. 20 /- Nephros Inc. (Ame...)

NEW YORK, Nov. 20 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today provided an update on its operations and strategy.

Recent Highlights and Events

• Appointed James Scibetta Chairman of the Board of Directors
• Appointed Ernest Elgin III President and CEO
• Submitted 510k for Mid-Dilution Hemodiafiltration products
• 510k for DSU filters in Renal Clinics
• Initial U.S. Sales of DSU filters for institutional infection control
• Developed initial concepts for prototypes for Department of Defense project
• Signed lease to relocate offices to River Edge, NJ
• Received approval for New Jersey Business Employment Incentive Program (BEIP) grant
• Reduced R&D personnel to redirect resources for sales and marketing

"Nephros has undergone major changes in its management structure and operational activities this year. We felt it was important to provide shareholders an overview of these changes and of our strategy for the future," said Ernest A. Elgin, President and CEO of Nephros.

OLpur MD220 Dialyzers and H2H Hemodiafiltration Module

Nephros has submitted a 510k application to the FDA for approval to market its leading-edge hemodiafiltration ("HDF") products for end-stage renal disease (ESRD) in the U.S. The application details Nephros's OLpur MD220 diafilter and Nephros's OLpur H2H Hemodiafiltration module. Nephros's OLpur MD220 is a filter designed expressly for HDF therapy that employs Nephros's proprietary Mid-Dilution Diafiltration technology. Nephros's OLpur H
'/>"/>